Plexus trust plans sale of 10,000 common shares

Accepted by SEC EDGAR 02/04/2026 - 04:57 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Plexus Corp. shareholder David and Constance Foate Joint Revocable Trust has filed a notice of proposed sale of 10,000 shares of common stock of Plexus through broker Robert W. Baird & Co. on the NASDAQ exchange, with an approximate sale date of February 4, 2026.

The filing shows an aggregate market value of 2037800 for these shares and notes that 27,092,389 common shares were outstanding. The shares to be sold were acquired through vesting of restricted and performance stock units in 2019, 2024, and 2025. Over the prior three months, the trust sold 5,000 common shares for gross proceeds of 1024467.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the PLXS Form 144 filing disclose about planned share sales?

The Form 144 discloses that David and Constance Foate Joint Revocable Trust plans to sell 10,000 Plexus common shares. The sale is to be executed through Robert W. Baird & Co. on NASDAQ, with an approximate sale date of February 4, 2026.

How many Plexus (PLXS) shares are being proposed for sale in this notice?

The notice covers a proposed sale of 10,000 Plexus common shares. These shares have an aggregate market value of 2,037,800 and are part of a broader base of 27,092,389 common shares reported as outstanding in the filing excerpt.

Who is the selling security holder in the Plexus (PLXS) Form 144 filing?

The selling holder is the David and Constance Foate Joint Revocable Trust, with an address at One Plexus Way in Neenah, Wisconsin. The filing provides this name and address in the section detailing securities sold during the past three months.

What prior Plexus (PLXS) share sales are reported in the last three months?

The filing reports that David and Constance Foate Joint Revocable Trust sold 5,000 Plexus common shares on February 2, 2026. These shares generated gross proceeds of 1,024,467, providing recent sale history for the same selling security holder.

How were the Plexus (PLXS) shares in this Form 144 acquired?

The shares were acquired through equity compensation. The filing lists vesting of restricted stock units in 2024 and 2025 and performance stock units in 2019, with dated entries and share amounts, all described as compensation from the issuer.

What information does the PLXS Form 144 provide about shares outstanding?

The document states that 27,092,389 Plexus common shares were outstanding. This figure is presented alongside the 10,000 shares proposed for sale and helps contextualize the size of the planned transaction relative to the total shares outstanding.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001223189
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Plexus Corp.
SEC File Number	001-14423
Address of Issuer	One Plexus Way Neenah WISCONSIN 54956
Phone	920-969-6000
Name of Person for Whose Account the Securities are To Be Sold	Dean Foate
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	ROBERT W BAIRD & CO. 777 E WISCONSIN AVE MILWAUKEE WI 53202	10000	2037800	27092389	02/04/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/29/2025	Vesting of Restricted Stock Units	Issuer			1979	01/29/2025	Compensation
Common	01/30/2024	Vesting of Restricted Stock Units	Issuer			1821	01/30/2024	Compensation
Common	02/12/2019	Vesting of Performance Stock Units	Issuer			6200	02/12/2019	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
David and Constance Foate Joint Revocable Trust One Plexus Way Neenah WI 54956	Common	02/02/2026	5000	1024467

144: Remarks and Signature

Remarks	Table II includes sales effected by the David and Constance Foate Joint Revocable Trust, of which the Reporting Person is a Co-Trustee.
Date of Notice	02/04/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Dean A. Foate, by Kate A. Gitter, Attorney-in-Fact
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)